Hydroxychloroquine Pill for Multiple Sclerosis
This trial is to test if a combination of two drugs can help reduce disability in people with secondary progressive multiple sclerosis.
- Secondary Progressive Multiple Sclerosis
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Does this research include young people in their twenties?
"The minimum age that a patient can be to enroll in this study is 18 and the maximum age is 60."
Are there any patients who have not yet been enrolled in this research?
"The website clinicaltrials.gov provides evidence that this study is still looking for patients to enroll. This research was first posted on October 1st, 2021 and the most recent update was on May 16th, 2022. They are recruiting from just 1 site but need a total of 35 individuals."
How many individuals are included in this research project?
"That is correct, the trial is still actively recruiting patients. The listing on clinicaltrials.gov shows that the study was posted on October 1st 2021 and updated most recently on May 16th 2022. They are hoping to enroll 35 patients from a single site."
If I meet the requirements, may I join this clinical trial?
"Those suffering from multiple sclerosis and between the ages of 18-60 may be eligible for this trial. So far, 35 patients have been enrolled."
Has the Hydroxychloroquine Pill undergone FDA approval?
"While Phase 2 trials have not yet provided data to support efficacy, there is enough information indicating Hydroxychloroquine Pill's safety to merit a score of 2."